Porton Newsletter - August 2025 Recap

Technical Enabling
Services & Solutions
Company Events
ESG
Marketing Activities

Others

News 2025-09-01

Porton to Showcase Integrated CDMO Expertise at BIOSPAIN 2025

News 2025-08-29

Porton's End-to-End CMC Development Accelerates Market Approval for Innovative ALK Inhibitor Dirozalkib (Xuanfeining) Tablets

As the sole CDMO service provider for the active pharmaceutical ingredient (API) of Dirozalkib

Become part of Porton's community to access personalized insights and resources.

First name *

Last name *

E-mail *

Company *

Subscribe for the Newsletter

Porton requires your contact information to reach out to you about our products and services. You can unsubscribe from these communications at any time. For details on how to unsubscribe and our commitment to protecting your privacy, please review our Legal Disclaimer Terms and Porton Privacy.

US: (609) 860-1300
CN: (86) 23-8608-3200

This website provides information on products tailored for a diverse audience and may include product details or information that are not readily accessible or valid in your country. Please note that we do not accept any responsibility for accessing such information in a manner that may violate any legal processes, regulations, registrations, or usage guidelines in your country of origin.

Become part of Porton's community to access personalized insights and resources.

Submit

By clicking “Submit” you agree to our Legal Disclaimer terms and conditions and the Porton Privacy and Cookies Policy.

US: (609) 860-1300
CN: (86) 23-8608-3200